Important Safety Information

Contraindication: Aimovig® is contraindicated in patients with serious hypersensitivity to erenumab-aooe or to any of the excipients. Reactions have included anaphylaxis and angioedema.

Hypersensitivity Reactions: Hypersensitivity reactions, including rash, angioedema, and anaphylaxis, have been reported with Aimovig® in post marketing experience. Most reactions were not serious and occurred within hours of administration, although some occurred more than one week after administration. If a serious or severe reaction occurs, discontinue Aimovig® and initiate appropriate therapy.

Constipation with Serious Complications: Constipation with serious complications has been reported following the use of Aimovig® in the postmarketing setting. There were cases that required hospitalization, including cases where surgery was necessary. The onset of constipation was reported after the first dose in a majority of these cases, but patients also reported later on in treatment. Aimovig® was discontinued in most reported cases. Constipation was one of the most common (up to 3%) adverse reactions reported in clinical studies.

Monitor patients treated with Aimovig® for severe constipation and manage as clinically appropriate. Concurrent use of medications associated with decreased gastrointestinal motility may increase the risk for more severe constipation and the potential for constipation-related complications.

Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of Aimovig® in the postmarketing setting. Many of the patients had pre-existing hypertension or risk factors for hypertension. There were cases requiring pharmacological treatment and, in some cases, hospitalization. Hypertension may occur at any time during treatment but was most frequently reported within seven days of dose administration. In the majority of the cases, the onset or worsening of hypertension was reported after the first dose. Aimovig® was discontinued in many of the reported cases.

Monitor patients treated with Aimovig® for new-onset hypertension, or worsening of pre-existing hypertension, and consider whether discontinuation of Aimovig® is warranted if evaluation fails to establish an alternative etiology.

Adverse Reactions: The most common adverse reactions in clinical studies (≥ 3% of Aimovig®-treated patients and more often than placebo) were injection site reactions and constipation.

Please see Aimovig® full Prescribing Information.


Indication

Aimovig® is indicated for the preventive treatment of migraine in adults.

In person or via telemedicine, the resources to help start your patients on Aimovig® are right here

We have gathered resources you may find helpful to start and support patient treatment with Aimovig®.

1. Starting patients on Aimovig®

Helping your patients get resources to start Aimovig®.

Download all starter materials

Dosing Reference Guides

Aimovig® is available in once-monthly doses of 70 mg and 140 mg.1 You can download the one-page reference guides below.

The 70 mg and 140 mg Instructions for Use and the Aimovig® Injection Video may also be helpful tools for your patients.

Download guides

Aimovig Ally™ Access Card

Your commercially insured eligible patients can get Aimovig® free for up to 12 dosesx If the patient’s health plan does not cover Aimovig® or requires a prior authorization, the patient can qualify for the Bridge to Commercial Coverage Offer and receive Aimovig® free for up to 12 doses, while pursuing approval from their health plan. No purchase necessary. See full Terms and Conditions below. or pay as little as a $5 monthly copay.x If Aimovig® is approved by the patient’s health plan, a patient pays a $5 copay per month, up to a maximum benefit of $3500 annually. This applies to patient out-of-pocket costs, including deductible, co-insurance, and copayments for Aimovig®. Patient is responsible for costs above the annual maximum. See full Terms and Conditions below.

Terms and Conditions apply. Click here for details.

Download

Getting Started Guide

A single resource guide, highlighting patient programs and tools to help patients new to Aimovig® start and stay on treatment as prescribed.

Download
2. Tools to help get your patients covered

More than 90% of prescriptions are approved by the patient's insurer.2 Aimovig® offers different options based on insurance coverage.

  • With the Aimovig Ally™ Access Card, commercially insured eligible patients can get Aimovig® free for up to 12 dosesx If the patient’s health plan does not cover Aimovig® or requires a prior authorization, the patient can qualify for the Bridge to Commercial Coverage Offer and receive Aimovig® free for up to 12 doses, while pursuing approval from their health plan. No purchase necessary. See full Terms and Conditions below. or pay as little as a
    $5 monthly copay.x If Aimovig® is approved by the patient’s health plan, a patient pays a $5 copay per month, up to a maximum benefit of $3500 annually. This applies to patient out-of-pocket costs, including deductible, co-insurance, and copayments for Aimovig®. Patient is responsible for costs above the annual maximum. See full Terms and Conditions below.
    Terms and Conditions apply. Click here to details.
  • Eligible commercially insured patients may be able to receive a 90-day supply of Aimovig® based on plan coverages. Eligible commercially insured patients enrolled in the Copay offer through the Aimovig Ally™ Access Card and may pay as little as $15 x Eligible commercially ensured patients enrolled in the Copay Offer may be able to use the Aimovig Ally™ Access Card for a 90-day supply of Aimovig®. Patients who qualify for the Bridge to Commercial Coverage Offer cannot use the Access Card for a 90-day supply of Aimovig®. See the full Terms and Conditions below. for a 90-day supply of Aimovig® ($5/month). Terms and Conditions apply. Click here to details.
  • If the patient's health plan does not cover Aimovig® or requires prior authorization (PA), the patient can qualify for the Bridge to Commercial Coverage Offer
  • Those who are uninsured or have insurance that excludes Aimovig® may be eligible under the Amgen Safety Net Foundation. Learn more here

Here are a few resources and forms that may be helpful for gaining access to Aimovig®.

Download all coverage materials

Prior Authorization Support

Prior Authorizations can be filed through covermymeds.

Access our PA checklist below.

Go to PA checklist

Sample Letter of Appeal

Template to request a review of a denied claim for Aimovig®.

Download

Sample Letter of Medical Necessity

Template to file documentation that Aimovig® is medically necessary.

Download
3. Telemedicine resources

The use of telemedicine and remote care services to treat patients has been increasing over time, and in some situations, may be essential. Here are a few telemedicine and remote care resources that you may find valuable.

CMS guidance on CPT and HCPCS codes:

https://www.cms.gov/newsroom/fact-sheets/medicare-telemedicine-health-care-provider-fact-sheet

AMA guidance on telemedicine coding:

https://www.ama-assn.org/practice-management/digital/ama-quick-guide-telemedicine-practice

AAN guidance on telemedicine and remote care:

https://www.aan.com/practice/telemedicine/

Disclaimer: These links are being provided as a convenience and for informational purposes only; they do not constitute an endorsement or an approval by Amgen and Novartis of any of the products, services, or opinions of the organization or individual. Amgen and Novartis bear no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links.

Have more questions?

Simply call 833-AIMOVIG (833-246-6844), Monday–Friday, 8:00 am–9:00 pm ET.
You’ll receive live support for your questions from knowledgeable representatives.

Terms and Conditions for Bridge to Commercial Coverage Offer (“Bridge Offer”): Aimovig® free for up to 12 doses over 24 months (whichever occurs first) from the first prescription filled under the Bridge Offer. Available if patient has a prescription, is commercially insured, and 18 years or older. This offer is not valid if patient is uninsured or receiving prescription reimbursement under any federal-, state-, or government-funded healthcare program, such as Medicare, Medicare Advantage, Medicare Part D, the Retiree Drug Subsidy Program, Medicaid, Medigap, Veterans Affairs (VA), the Department of Defense (DoD), or TRICARE or where prohibited by law. Cash Discount Cards and other noninsurance plans are not valid as primary under this offer. If at any time patient begins receiving coverage under any such federal-, state-, or government funded healthcare program, patient will no longer be able to use this offer and patient must call 833-AIMOVIG to stop participation. By participating in this offer, patient acknowledges intent to pursue insurance coverage for Aimovig® with their healthcare provider. Ongoing eligibility requires that patient has a prior authorization or medical exception denied within 90 days of first use of offer. Once insurance approval is obtained, patient is no longer eligible for this offer. No purchase necessary. This is not health insurance. Participation is not a guarantee of insurance coverage. This offer is not renewable. Valid in the United States, Puerto Rico, and the US territories. Other restrictions may apply. This offer is subject to change or discontinuation without notice.

Terms and Conditions for Copay Offer: Pay a $5 copay per month, up to a maximum benefit of $3500 annually. Available if patient has a prescription, is commercially insured, and 18 years or older. This offer is not valid if patient is uninsured or receiving prescription reimbursement under any federal-, state-, or government-funded healthcare program, such as Medicare, Medicare Advantage, Medicare Part D, the Retiree Drug Subsidy Program, Medicaid, Medigap, Veterans Affairs (VA), the Department of Defense (DoD), or TRICARE or where prohibited by law. Cash Discount Cards and other noninsurance plans are not valid as primary under this offer. If at any time patient begins receiving coverage under any such federal-, state-, or government-funded healthcare program, patient will no longer be able to use this offer and patient must call 833-AIMOVIG to stop participation. Patient may not seek reimbursement for value received from this offer from any third-party payers, including flexible spending accounts or healthcare savings accounts. This is not health insurance. Participation is not a guarantee of insurance coverage. Valid in the United States, Puerto Rico, and the US territories. Other restrictions may apply. This offer is subject to change or discontinuation without notice. If you become aware that your health plan or pharmacy benefit manager does not allow the use of manufacturer copay support as part of your health plan design, you agree to comply with your obligations, if any, to disclose your use of the card to your insurer. This offer is ongoing and in order to remain eligible, patient must re-enroll every 12 months by visiting www.aimovigaccesscard.com/ or by calling 833-AIMOVIG (833-246-6844).

Indication

Aimovig® is indicated for the preventive treatment of migraine in adults.

Important Safety Information

Contraindication: Aimovig® is contraindicated in patients with serious hypersensitivity to erenumab-aooe or to any of the excipients. Reactions have included anaphylaxis and angioedema.

Hypersensitivity Reactions: Hypersensitivity reactions, including rash, angioedema, and anaphylaxis, have been reported with Aimovig® in post marketing experience. Most reactions were not serious and occurred within hours of administration, although some occurred more than one week after administration. If a serious or severe reaction occurs, discontinue Aimovig® and initiate appropriate therapy.

Constipation with Serious Complications: Constipation with serious complications has been reported following the use of Aimovig® in the postmarketing setting. There were cases that required hospitalization, including cases where surgery was necessary. The onset of constipation was reported after the first dose in a majority of these cases, but patients also reported later on in treatment. Aimovig® was discontinued in most reported cases. Constipation was one of the most common (up to 3%) adverse reactions reported in clinical studies.

Monitor patients treated with Aimovig® for severe constipation and manage as clinically appropriate. Concurrent use of medications associated with decreased gastrointestinal motility may increase the risk for more severe constipation and the potential for constipation-related complications.

Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of Aimovig® in the postmarketing setting. Many of the patients had pre-existing hypertension or risk factors for hypertension. There were cases requiring pharmacological treatment and, in some cases, hospitalization. Hypertension may occur at any time during treatment but was most frequently reported within seven days of dose administration. In the majority of the cases, the onset or worsening of hypertension was reported after the first dose. Aimovig® was discontinued in many of the reported cases.

Monitor patients treated with Aimovig® for new-onset hypertension, or worsening of pre-existing hypertension, and consider whether discontinuation of Aimovig® is warranted if evaluation fails to establish an alternative etiology.

Adverse Reactions: The most common adverse reactions in clinical studies (≥ 3% of Aimovig®-treated patients and more often than placebo) were injection site reactions and constipation.

Please see Aimovig® full Prescribing Information.

References: 1. Aimovig® (erenumab-aooe) Prescribing Information. Thousand Oaks, CA: Amgen Inc; 2020. 2. Data on file, Amgen; [IQIVIA MMIT Coverage Access Metrics WE 05/08/20 to 05/29/20].